FINWIRES · TerminalLIVE
FINWIRES

NSE:ZYDUSLIFE

12 stories mentioning NSE:ZYDUSLIFEUpdated 3d ago

Every FINWIRES story that references NSE:ZYDUSLIFE, newest first.

Asia

Zydus Lifesciences Ordered to Pay Deficient Stamp Duty, Fines for Asset Acquisition

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has been ordered to pay an amount of 108.5 million Indian rupees in deficient stamp duty related to the acquisition of land, building, plant, and machinery assets from Sterling Biotech.The amount, comprising a deficient stamp duty of 53.5 million rupees and penalties of 55.1 million rupees, has been ordered by the Office of the Superintendent of Stamps, Gandhinagar, Gujarat, according to a Wednesday Indian bourse filing.The order came after the authority determined the market value of the assets was higher than the value adopted for stamp duty purposes.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences Resumes Operations in Ahmedabad, India

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) restarted operations at its facilities in India's Ahmedabad region after temporarily suspending some activities due to torrential rain and waterlogging.Operations at the affected sites were halted as a precautionary measure and are being restored as weather conditions improve, according to an Indian bourse filing on Saturday.Shares of the company rose nearly 1% in Monday morning trade.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences Gets India Nod for Phase III Desidustat Trial in Sickle Cell Disease

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has received approval to conduct a Phase III clinical trial of Desidustat in patients with sickle cell disease.The 203-day study, to be conducted in collaboration with the Indian Council of Medical Research, will evaluate the efficacy and safety of Desidustat oral tablets for treating anemia associated with the disease, according to an Indian bourse filing on Thursday.The trial is expected to enroll 164 patients.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences Signs MoU With Apollo Hospitals for Multi-Cancer Detection Test; Shares Up 3%

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has signed a memorandum of understanding (MoU) with Apollo Hospitals to offer the Shield Multi-Cancer Detection test in India.The MoU follows Zydus Lifesciences' exclusive arrangement with Guardant Health to introduce the blood-based cancer screening test in the country, according to a stock exchange filing on Friday.Shield MCD is a methylation-based blood test designed to screen for multiple cancers, including breast, lung, colorectal, and prostate cancers, using a single blood sample.Shares of the company rose over 3% in recent trade.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences to Form 50:50 JV With Sunshine Healthcare in Sri Lanka

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has entered into a share subscription and shareholders' agreement with Sunshine Healthcare Lanka and Zydus Sunshine Lifesciences to acquire a 50% stake in the latter.Post investment, Zydus Sunshine will operate as a 50:50 joint venture between Zydus and Sunshine Healthcare and will set up a pharmaceutical manufacturing facility in Sri Lanka's Horana Export Processing Zone, according to a stock exchange filing on Friday.The investment of up to $5 million will be completed within 90 working days of execution of the agreement.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences Completes Acquisition of US-Based Assertio Holdings

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321), through its wholly-owned subsidiary, Zara Merger Sub, has completed the acquisition of all outstanding shares of common stock of NASDAQ-listed Assertio Holdings, according to a Tuesday filing to the Indian stock exchanges.The purchase was done at $23.50 per share of common stock of the U.S.-based specialty oncology pharmaceutical company Assertio, as part of a merger deal amounting to a total consideration of $166.3 million on a fully diluted basis.After the completion of the merger, Assertio will be the surviving entity, in which all shares of common stock not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $23.50 offer price per common share.Assertio will become a wholly-owned subsidiary of the company, and its common stock will no longer be listed or traded on the Nasdaq, the statement said.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences Unit Secures Reduction in GST Tax Demands

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) said appellate authorities in Chhattisgarh, India, have substantially reduced tax demands and penalties imposed on its wholly owned subsidiary, Zydus Healthcare, in input tax credit (ITC) cases for financial years 2018-19 and 2019-20, according to a Tuesday filing on Indian bourses.For the financial year 2018-19, demand was reduced to 24,000 rupees from 2.9 million rupees, including penalty, the company said in the filing.For the financial year 2019-20, demand was cut to 20,000 rupees from around 1.3 million rupees, including penalty, it added.The relief was granted through orders passed by the Appellate Additional Commissioner of State, Chhattisgarh, the company said.Shares of Zydus Lifesciences rose 1% in recent trade.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences Receives USFDA Warning Letter for Baddi Facility

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) said it received a warning letter from the U.S. Food and Drug Administration related to its formulations manufacturing facility in Baddi, Himachal Pradesh, according to a Wednesday filing on Indian bourses.The warning letter was issued in response to a records request under the Federal Food, Drug, and Cosmetic Act, the company said. It relates to observations regarding the use of purified talc that did not meet current U.S. Pharmacopeia requirements.Zydus said the letter is not linked to an on-site inspection and does not affect current operations or supplies from the facility.

BOM:532321NSE:ZYDUSLIFE
Asia

Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,200 From INR1,100, Keeps at Buy

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has an average rating of overweight and mean price target of 1,031.39 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

BOM:532321NSE:ZYDUSLIFE
Asia

Indian Equities Jump on Wednesday as US-Iran Deal Hopes Lift Sentiment

Indian benchmark indices ended sharply higher on Wednesday as reports of a possible U.S.-Iran deal supported global risk sentiment.The BSE Sensex rose 940.73 points, or 1.22%, to close at 77,958.52, while the NSE Nifty 50 gained 298.15 points, or 1.24%, to settle at 24,330.95.Markets advanced on expectations that the U.S. and Iran may be close to resolving their conflict, which had pushed energy prices higher in recent sessions. Hopes of easing geopolitical risks supported sentiment and helped drive broad-based buying.In economic news, Services activity in Indian strengthened in April, with the HSBC India Services PMI rising to 58.8 from 57.5, supported by firm domestic demand and e-commerce growth. New orders saw the fastest expansion in five months, aided by pricing strategies and demand for logistics and relocation services. However, export growth slowed to a five-month low amid Middle East tensions and weak tourism.In earnings news, Aditya Birla Real Estate (NSE:ABREL, BOM:500040) gained nearly 5% after reporting a profit of 108.4 million rupees in Q4, compared with a loss of 1.31 billion rupees a year earlier, according to a filing. Revenue from operations declined to 981.9 million rupees from 4.08 billion rupees.Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) rose over 3% after receiving seven observations from the US FDA following an inspection of its Ahmedabad facility, according to a Wednesday filing.

^BSENifty 50BOM:500040BOM:532321NSE:ABRELNSE:ZYDUSLIFE
Asia

Zydus Gets Seven Observations from US FDA After Ahmedabad, India Unit Inspection; Shares Up 3%

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) received seven observations from the US Food and Drug Administration (US FDA) following the inspection of its Unit 9 facility located at Zydus Biotech Park in Ahmedabad, India, according to a Wednesday filing to the India stock exchanges.The regulator inspected the Ahmedabad unit from April 27 to May 5.The company plans to closely work with the USFDA for work on resolving the observations expeditiously.The company's shares were up nearly 3% in recent trade.

BOM:532321NSE:ZYDUSLIFE
Asia

Zydus Lifesciences Gets US FDA Approval for Oncology Injectable Manufacturing Site

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has received the establishment inspection report and approval letter from the US Food and Drug Administration for its oncology injectable manufacturing site in Ahmedabad, India.The US FDA conducted a pre-approval inspection at the facility in November 2025 in relation to the new isolator injectable line, according to a Thursday filing to the Indian stock exchanges.

BOM:532321NSE:ZYDUSLIFE

Track with the FINWIRES app suite

FolioX
FolioX
Track NSE:ZYDUSLIFE in your portfolio
WheelAI
WheelAI
Analyze NSE:ZYDUSLIFE options with the wheel strategy
StockInsider
StockInsider
See market sentiment on NSE:ZYDUSLIFE